Unintended effects of orphan product designation for rare neurological diseases

Annals of Neurology

Volumn 72, Issue 4, 2012, Pages 481-490

  Murphy, Sinéad M ^a,b   Puwanant, Araya ^c   Griggs, Robert C ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AGALSIDASE BETA; ALENDRONIC ACID; ALGLUCERASE; ALPHA GLUCOSIDASE; ARIPIPRAZOLE; BETA1A INTERFERON; BEVACIZUMAB; BIOLOGICAL PRODUCT; BORTEZOMIB; BOSENTAN; BOTULINUM TOXIN; BOTULINUM TOXIN A; COLCHICINE; CORTICOTROPIN; ETANERCEPT; GABAPENTIN; GENZYME; GLATIRAMER; IMATINIB; IMIGLUCERASE; INFLIXIMAB; INTERFERON BETA SERINE; LAMOTRIGINE; LARONIDASE; LENALIDOMIDE; LEUPRORELIN; MELOXICAM; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; ORPHAN DRUG; PACLITAXEL; PEGINTERFERON ALPHA2A; PEMETREXED; PRAMIPEXOLE; RALOXIFENE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ROFECOXIB; TACROLIMUS; TADALAFIL; TEMOZOLOMIDE; TETRABENAZINE; TIOTROPIUM BROMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACUTE LEUKEMIA; ANEMIA; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; CEREBRAL PALSY; CHRONIC LEUKEMIA; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DYSTONIA; ENTERITIS; ENZYME REPLACEMENT; FABRY DISEASE; FAMILIAL MEDITERRANEAN FEVER; FOOD AND DRUG ADMINISTRATION; GAUCHER DISEASE; GILLES DE LA TOURETTE SYNDROME; GLYCOGEN STORAGE DISEASE TYPE 2; GOUT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEMOPHILIA; HUMAN; HUNTINGTON CHOREA; HURLER SYNDROME; INFANTILE SPASM; JUVENILE RHEUMATOID ARTHRITIS; LAW; LUNG FIBROSIS; LYMPHOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RARE DISEASE; RESOURCE ALLOCATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ADRENOCORTICOTROPIC HORMONE; ALPHA-GLUCOSIDASES; ANTI-DYSKINESIA AGENTS; BIOLOGICAL AGENTS; CHILD; DRUG APPROVAL; HEALTH CARE SECTOR; HUMANS; INFANT; NERVOUS SYSTEM DISEASES; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; SPASMS, INFANTILE; TETRABENAZINE; UNITED STATES;

EID: 84868157585     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23672     Document Type: Article

References (72)

1. Department of Health and Human Services: Office of Inspector General. The Orphan Drug Act: implementation and impact. May 2001. Available at: http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf Accessed February 14, 2011.
2. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009; 96: 20-26.
3. National Institutes of Health: Office of Rare Diseases. Available at: http://rarediseases.info.nih.gov/Resources/Rare-Diseases-Information.aspx Accessed February 4, 2011.
4. Wastfelt M, Fadeel B, Henter JI,. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 2006; 260: 1-10.
5. Krantz JC Jr,. New drugs and the Kefauver-Harris amendment. J New Drugs 1966; 6: 77-79.
6. Field MJ, Boat TF,. Rare diseases and orphan product. 1st ed. Washington, DC: National Academies Press, 2010.
7. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J,. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008; 3: 33.
8. Braun MM, Farag-El-Massah S, Xu K, Cote TR,. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010; 9: 519-522.
9. US Food and Drug Administration. Information on the Orphan Products Grants Program. May 2010. Available at: http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/ WhomtoContactaboutOrphanProductDevelopment/ucm134580.htm Accessed February 14, 2011.
10. US Food and Drug Administration. Search orphan drug designations and approvals. Available at: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/ index.cfm Accessed February 12, 2011.
11. Haffner ME, Whitley J, Moses M,. Two decades of orphan product development. Nat Rev Drug Discov 2002; 1: 821-825.
12. Kesselheim AS,. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med 2010; 363: 1855-1862.
13. US Department of Health and Human Services: Office of Extramural Research. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. Available at: http://grants.nih.gov/grants/ funding/sbirsttr-programs.htm Accessed February 12, 2011.
14. Patient Protection and Affordable Care Act. Public Law 111-148, 111th Congress, H.R. 3590, March 23, 2010. Available at: http://www.gpo.gov/fdsys/pkg/ PLAW-111publ148/pdf/PLAW-111publ148.pdf Accessed October 12, 2011.
15. Preserving Access to Orphan Drugs Act of 2011. H.R. 2672, 112th Congress. Available at: http://thomas.loc.gov/ Accessed October 12, 2011.
16. Medical Innovation Prize Act. S. 1137, 112th Congress. Available at: http://thomas.loc.gov/cgi-bin/query/z?c112:S.1137.IS Accessed October 12, 2011.
17. Dalby MA,. Effect of tetrabenazine on extrapyramidal movement disorders. Br Med J 1969; 2: 422-423.
18. Huntington Study Group,. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66: 366-372.
19. Pollock DL,. Blame Canada (and the rest of the world): the twenty-year war on imported prescription drugs. Bepress legal series 2005, paper 806. Available at: http://law.bepress.com/cgi/viewcontent.cgi?article= 4130&context=expresso Accessed October 12, 2011.
20. FDA Personal Use Import Policy. Available at: http://www.ceri.com/import. htm Accessed October 12, 2011.
21. US Food and Drug Administration. Xenazine NDA approval. August 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2008/ 021894s000ltr.pdf Accessed July 28, 2011.
22. Fallon Community Health Plan Department of Pharmacy Services. Prior authorization approval criteria: Xenazine (tetrabenazine). Available at: http://www.fchp.org/∼/media/Files/FCHP/Imported/Xenazine-tetrabenazine.pdf. ashx Accessed March 1, 2011.
23. British National Formulary. 61st ed. London, UK: BMJ Group and RPS Publishing, 2011
24. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97: 375-379.
25. Watsan R,. Drug price soars from $1,650 to $23,000 per vial to treat babies with infantile spasms: parents and physicians react. September 2007. Available at: http://professionals.epilepsy.com/page/ar-1189197304.html Accessed February 10, 2011.
26. Questcor Pharmaceuticals launches Acthar for the treatment of infantile spasms. November 2010. Available at: http://www.investorguide.com/stock-news- show.php?story-id=35337060&topic=QCOR Accessed February 6, 2011.
27. Wellman-Labadie O, Zhou Y,. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2010; 95: 216-228.
28. Genzyme Corporation. Product lists. Available at: http://www.genzyme.com/ business/biz-home.asp Accessed February 10, 2011.
29. Wagner KR,. Enzyme replacement for infantile Pompe disease: the first step toward a cure. Neurology 2007; 68: 88-89.
30. Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009; 19: 113-117.
31. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68: 99-109.
32. US Food and Drug Administration. FDA news release. May 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm213212.htm Accessed February 4, 2011.
33. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362: 1396-1406.
34. Clark T, Berkrot B,. Update 2: Genzyme wins FDA approval for Pompe drug. May 2010. Available at: http://www.reuters.com/article/2010/05/25/genzyme- idUSN2513053720100525?pageNumber=1 Accessed February 8, 2011.
35. CVS Caremark. Specialty TrendsRx® Alert. Available at: https://www.caremark.com/portal/asset/SpecialtyTrendsRxAlert-Lumizyme.pdf Accessed April 10, 2011.
36. Scharf SF,. Orphan drugs: the question of products liability. Am J Law Med 1985; 10: 491-513.
37. Joppi R, Bertele V, Garattini S,. Orphan drug development is progressing too slowly. Br J Clin Pharmacol 2006; 61: 355-360.
38. Mitsumoto J, Dorsey ER, Beck CA, et al. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009; 66: 184-190.
39. Wheadon DE,. Market exclusivity for biologics. N Engl J Med 2010; 362: 661; author reply 661-662.
40. US Food and Drug Administration. FDA approves colchicine for acute gout, Mediterranean fever. July 2009. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2009/ucm174620.htm Accessed February 12, 2011.
41. Kesselheim AS, Solomon DH,. Incentives for drug development-the curious case of colchicine. N Engl J Med 2010; 362: 2045-2047.
42. Derek Lowe,. Colchicine's price goes through the roof. Available at: http://pipeline.corante.com/archives/2010/04/14/colchicines-price-goes-through- the-roof.php Accessed October 12, 2011.
43. FDA approval of ancient remedy sends price soaring. Available at: http://www.cbsnews.com/2100-18563-162-20118283.html Accessed March 1, 2011.
44. The price of gout drug, colchicine, goes up. Available at: http://www.arthritistoday.org/news/colchicine-gout-drug-price053.php Accessed March 1, 2011.
45. Grody WW, Getzug T,. Colchicine's other indication-effect of FDA action. N Engl J Med 2010; 363: 2267-2268.
46. National Institutes of Health: Office of Rare Diseases Research. Rare diseases and related terms. Available at: http://rarediseases.info.nih.gov/ RareDiseaseList.aspx?PageID=1 Accessed July 28, 2011.
47. Goldman DP, Joyce GF, Zheng Y,. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007; 298: 61-69.
48. US Food and Drug Administration: Drug Safety and Availability. Hawaii: Governor Linda Lingle. September 2009. http://www.fda.gov/Drugs/DrugSafety/ ucm179204.htm Accessed February 12, 2011.
49. Engelberg AB, Kesselheim AS, Avorn J,. Balancing innovation, access, and profits-market exclusivity for biologics. N Engl J Med 2009; 361: 1917-1919.
50. Pinxten W, Denier Y, Dooms M, et al. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. J Med Ethics 2012; 38: 148-153.
51. Lee TH, Emanuel EJ,. Tier 4 drugs and the fraying of the social compact. N Engl J Med 2008; 359: 333-335.
52. IMS Consulting. Orphan drugs: rarity no guarantee of access. Available at: http://www.onlymedics.com/documents/download-medics-KsCzr.pdf Accessed October 12, 2011.
53. Orofino J, Soto J, Casado MA, Oyaguez I,. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 2010; 8: 301-315.
54. BCC Research. Global market for orphan drugs. Available at: http://www.bccresearch.com/report/orphan-drugs-market-phm038b.html Accessed March 30, 2011.
55. BCC Research. Global markets for orphan drugs. Available at: http://www.bccresearch.com/report/orphan-drugs-market-phm038c.html?tab= scope&highlightKeyword=orphan+drugs+sales+2008 Accessed March 31, 2011.
56. Orphan drugs. Nature. 2010. Available at: http://www.nature.com/news/ 2010/101201/pdf/468604a.pdf Accessed October 11, 2011.
57. Denis A, Mergaert L, Fostier C, et al. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 2010; 13: 295-301.
58. Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659-665.
59. Acorda's MS drug Ampyra looks good now, but that probably won't last. Available at: http://www.cbsnews.com/8301-505123-162-43240646/acordas-ms-drug- ampyra-looks-good-now-but-that-probably-wont-last/ Accessed March 31, 2011.
60. Multiple sclerosis: 4-aminopyridine. Available at: http://www. thecompounder.com/alternative-treatments/multiple-sclerosis/4-aminopyridine Accessed March 31, 2011.
61. McCabe C, Claxton K, Tsuchiya A,. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331: 1016-1019.
62. Burls A, Austin D, Moore D,. Commissioning for rare diseases: view from the frontline. BMJ 2005; 331: 1019-1021.
63. Richards T,. Orphan diseases: which ones do we adopt? BMJ 2008; 337: a1225.
64. Roos JC, Hyry HI, Cox TM,. Orphan drug pricing may warrant a competition law investigation. BMJ 2010; 341: c6471.
65. Cheung RY, Cohen JC, Illingworth P,. Orphan drug policies: implications for the United States, Canada, and developing countries. Health Law J 2004; 12: 183-200.
66. Danzon PM,. At what price? Nature 2007; 13: 176-179.
67. Danzon PM, Towse A, Mulcahy AW,. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff (Millwood) 2011; 30: 1529-1538.
68. Gucev ZS, Tasic V, Polenakovic M,. On rare and "super-rare" diseases: an insight from the Republic of Macedonia. Prilozi 2011; 32: 7-11.
69. Olivier C, Williams-Jones B. Pharmacogenomic technologies: a necessary "luxury" for better global public health? Global Health 2011; 7: 30.
70. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy 2010; 97: 173-179.
71. National Institute for Health and Clinical Excellence. Appraising Orphan Drugs Proposal. Available at: http://www.nice.org.uk/aboutnice/whoweare/ seniormanagementteam/meetings/2005/12july2005/appraising-orphan-drugs.jsp Accessed March 10, 2012.
72. Schlander M,. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics 2008; 34: 534-539.